



PIK3CA-Related Overgrowth Spectrum

Synonym: PROS

Ghayda Mirzaa, MD, FAAP, FACMG,¹ John M Graham, Jr, MD, ScD,² and Kim Keppler-Noreuil, MD, FAAP, FACMG³

Created: August 15, 2013; Revised: April 6, 2023.

Summary

Clinical characteristics

PIK3CA-related overgrowth spectrum (PROS) encompasses a range of clinical findings in which the core features are congenital or early-childhood onset of segmental/focal overgrowth with or without cellular dysplasia. Prior to the identification of *PIK3CA* as the causative gene, PROS was separated into distinct clinical syndromes based on the tissues and/or organs involved (e.g., MCAP [*megalencephaly-capillary malformation*] syndrome and CLOVES [*congenital lipomatous asymmetric overgrowth of the trunk, lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, skeletal and spinal anomalies*] syndrome). The predominant areas of overgrowth include the brain, limbs (including fingers and toes), trunk (including abdomen and chest), and face, all usually in an asymmetric distribution. Generalized brain overgrowth may be accompanied by secondary overgrowth of specific brain structures resulting in ventriculomegaly, a markedly thick corpus callosum, and cerebellar tonsillar ectopia with crowding of the posterior fossa. Vascular malformations may include capillary, venous, and less frequently, arterial or mixed (capillary-lymphatic-venous or arteriovenous) malformations. Lymphatic malformations may be in various locations (internal and/or external) and can cause various clinical issues, including swelling, pain, and occasionally localized bleeding secondary to trauma. Lipomatous overgrowth may occur ipsilateral or contralateral to a vascular malformation, if present. The degree of intellectual disability appears to be mostly related to the presence and severity of seizures, cortical dysplasia (e.g., polymicrogyria), and hydrocephalus. Many children have feeding difficulties that are often multifactorial in nature. Endocrine issues affect a small number of individuals and most commonly include hypoglycemia (largely hypoinsulinemic hypoketotic hypoglycemia), hypothyroidism, and growth hormone deficiency.

Author Affiliations: 1 Seattle Children's Research Institute, Seattle, Washington; Email: ghayda.mirzaa@seattlechildrens.org. 2 Cedars Sinai Medical Center, Los Angeles, California; Email: john.graham@cshs.org. 3 University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; Email: keppelnoreu@wisc.edu.

Diagnosis/testing

The diagnosis of PROS is established in a proband with suggestive findings and a heterozygous mosaic (or rarely, constitutional) activating pathogenic variant in *PIK3CA*. Sequence analysis of DNA derived from clinically affected tissue samples – preferably from freshly obtained dermal biopsy overlying an affected area, from surgical excision of the overgrown tissue, or from uncultured tissues (such as skin fibroblasts or other tissues) – should be prioritized for genetic testing. Targeted capture of the entire *PIK3CA* coding region followed by next-generation sequencing at very deep coverage is recommended for somatic variant detection, as it allows for detection of very low levels of mosaicism throughout the gene.

Management

Targeted therapy: Alpelisib (VIJOICE®) 50 mg orally with food once a day (at about the same time every day) for those between age two years and <18 years with PROS. In those age six years or older, the dose may be increased to 125 mg once a day after 24 weeks. A starting dose of 250 mg orally with food once a day (at about the same time every day) has been approved for those age ≥18 years. Alpelisib has been approved specifically for the reduction of overgrowth, vascular lesions, and other functional complications. To date, it is unknown whether this drug has any efficacy in treating the neurologic manifestations of PROS (as, e.g., in MCAP syndrome).

Supportive care: Significant or lipomatous segmental overgrowth may require debulking; scoliosis and leg-length discrepancy may require orthopedic care and surgical intervention. Neurologic complications (e.g., obstructive hydrocephalus, increased intracranial pressure, progressive and/or symptomatic cerebellar tonsillar ectopia or Chiari malformation, and epilepsy in those with brain overgrowth/malformations) may warrant neurosurgical intervention. Depending on the type of vascular malformations, sclerotherapy, laser therapy, or oral medications such as sirolimus may be used. Similarly, lymphatic malformations may be treated through oral medications or careful surgical debulking, preferably by a vascular anomalies team. For those with pain, evaluation for the source of pain and treatment of the underlying cause is recommended. For those with growth hormone deficiency, evaluation of the hypothalamic-pituitary-adrenal axis is warranted; a trial of growth hormone therapy may be considered with careful monitoring of linear growth and overgrowth. Severe persistent hypoglycemia has been reported, and requires evaluation and ongoing treatment, which can include cornstarch administration. Routine treatment of the following, when present, is indicated: cardiac and renal abnormalities; intellectual disabilities and behavior issues; polydactyly and foot deformities; coagulopathy or thrombosis; Wilms tumor; and hypothyroidism.

Surveillance: At each visit: measurement of growth parameters including head circumference, length of arms, hands, legs, and feet; assess for new neurologic manifestations (seizures, changes in tone, and other signs/symptoms of Chiari malformation); monitor developmental progress and behavior; assess motor skills; clinical assessment for scoliosis and abdominal examination for organomegaly and/or abdominal masses. Serial head MRI imaging is recommended, with frequency based on the severity of findings on initial assessment and the degree of brain maturation. For those with CNS overgrowth or dysplasia, brain MRI every six months until age two years and then annually until age eight years to monitor specifically for progressive hydrocephalus and Chiari malformation. As clinically indicated: clinical assessment and monitoring of any vascular and/or lymphatic malformations; radiographs of the limbs in those with overgrowth of a limb or portion of a limb; ultrasound or MRI follow up in those with truncal overgrowth; spinal MRI in those with scoliosis or deformities that affect the spine; blood glucose monitoring and evaluation of the hypothalamic-pituitary-adrenal axis for those with persistent hypoglycemia, particularly if they require ongoing treatment for hypoglycemia. Hematology consultation with recommendations for assessment for thrombosis and coagulopathy risk after any surgical intervention, particularly in those with the CLOVES phenotype and/or those with vascular malformations. Consideration of renal ultrasound every three months until age eight years (tumor screening for Wilms tumor is controversial).

Genetic counseling

PROS disorders are not known to be inherited, as most identified pathogenic variants are somatic (mosaic). No confirmed vertical transmission or sib recurrence has been reported to date. The risk to sibs of a proband with somatic mosaicism for a pathogenic variant in *PIK3CA* would be expected to be the same as in the general population. All but a few affected individuals with PROS have had somatic mosaicism for a *PIK3CA* pathogenic variant, suggesting that mutation occurred post fertilization in one cell of the multicellular embryo. Therefore, the risk for transmission to offspring is expected to be less than 50%.

GeneReview Scope

PIK3CA-Related Overgrowth Spectrum (PROS): Included Phenotypes ^{1, 2}

- Megalencephaly-capillary malformation (MCAP) syndrome
- Dysplastic megalencephaly (DMEG), hemimegalencephaly (HMEG) and focal cortical dysplasia (FCD)
- Congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal (CLOVES) syndrome
- Klippel-Trenaunay syndrome
- CLAPO syndrome
- Isolated tissue dysplasia-overgrowth phenotypes: lymphatic malformations, vascular malformations, venous malformations, lipomatosis
- Fibroadipose hyperplasia or overgrowth (FAO)
- Hemihyperplasia multiple lipomatosis (HHML)
- Macrodactyly
- Fibroadipose infiltrating lipomatosis / facial infiltrative lipomatosis

For synonyms and outdated names see Nomenclature.

1. For other genetic causes of these phenotypes see Differential Diagnosis.

2. Sadick et al [2018]

Diagnosis

PIK3CA-related overgrowth spectrum (PROS) encompasses a range of clinical findings in which the **core features** are congenital or early-childhood onset of segmental/focal overgrowth with or without cellular dysplasia in the absence of a family history of similarly affected individuals (i.e., single occurrence in a family). Prior to the identification of *PIK3CA* as the causative gene, PROS was separated into distinct clinical syndromes based on the tissues and/or organs involved (see *GeneReview Scope*).

Suggestive Findings

PROS **should be considered** in individuals with the following clinical, brain MRI, and family history findings [Keppler-Noreuil et al 2015, Mirzaa et al 2016, Kuentz et al 2017].

Clinical features

- Overgrowth of any of a wide variety of tissues including (but not limited to) brain, adipose, vascular, muscle, skeletal, nerve
- Vascular malformations including (but not limited to) capillary, venous, arteriovenous, or mixed malformations
- Lymphatic malformations
- Cutaneous findings including epidermal nevi and hyperpigmented macules
- Single or multiple digital anomalies of the hands or feet (e.g., macrodactyly, syndactyly, polydactyly, sandal-toe gap)
- Kidney malformations

- Benign tumors, with the exceptions of Wilms tumor and neuroblastomatosis (i.e., diffuse or multifocal clusters of persistent embryonal cells)

Brain MRI findings. Focal brain overgrowth (with or without cortical dysplasia) including:

- Hemimegalencephaly (HMEG)
- Focal cortical dysplasia (FCD)
- Dysplastic megalencephaly (DMEG)

Family history. Because *PIK3CA* is typically caused by a *de novo* mosaic pathogenic variant, most probands represent a simplex case (i.e., a single occurrence in a family). Rarely, the family history may be consistent with autosomal dominant inheritance (e.g., affected males and females in multiple generations).

Establishing the Diagnosis

The diagnosis of PROS is **established** in a proband with suggestive findings and a heterozygous mosaic (or rarely, constitutional) activating pathogenic variant in *PIK3CA* [Keppler-Noreuil et al 2015] (see Table 1 and Molecular Genetics).

Molecular diagnosis. Molecular genetic testing approaches typically include use of **targeted testing** (single-gene testing or multigene panel), although **comprehensive genomic testing** (exome sequencing, genome sequencing) is available. Because the majority of reported *PIK3CA* pathogenic variants are postzygotic (and thus mosaic), more than one tissue (excluding blood in most cases) may need to be tested:

- Experience suggests that sequence analysis of DNA derived from clinically affected tissue samples – preferably from freshly obtained dermal biopsy overlying an affected area, from surgical excision of the overgrown tissue, or from uncultured tissues (e.g., skin fibroblasts or other tissues) – should be prioritized for genetic testing.
- The level of mosaicism for an activating variant in affected tissues or cultured cells is extremely variable [Keppler-Noreuil et al 2014, Kuentz et al 2017].
- Testing of blood or DNA isolated from blood is not recommended based on current technologies, as *PIK3CA* pathogenic variants have not been identified in blood except in two of 24 individuals with megalencephaly-capillary malformation (MCAP) syndrome, who had an apparently *de novo* germline pathogenic variant in *PIK3CA* [Rivière et al 2012].

Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those in whom the diagnosis of PROS has not been considered **may** be diagnosed using genomic testing (see Option 2), if an appropriate sample is used.

Option 1

When the phenotypic findings suggest a diagnosis of PROS, molecular genetic testing approaches can include **single gene testing** or use of a **multigene panel** that includes *PIK3CA*.

- **Single-gene testing.** Sequence analysis of *PIK3CA* may be performed on an appropriate sample (see above) and can detect missense variants (see Molecular Genetics for a summary of appropriate laboratory techniques to detect low levels of mosaicism).

Note: (1) The pathogenic variants observed in PROS have all been associated with gain of function; thus, gene-targeted deletion/duplication analysis is not recommended. (2) Failure to detect an activating *PIK3CA* pathogenic variant does not exclude a diagnosis of PROS in individuals with suggestive findings, given that a low level of mosaicism is observed in many affected individuals [Kurek et al 2012, Lee et al 2012, Lindhurst et al 2012, Jansen et al 2015, Mirzaa et al 2016].

- **A multigene panel** that includes *PIK3CA* and other genes of interest (see Differential Diagnosis) on an appropriate sample (see above) may be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.

For an introduction to multigene panels click [here](#). More detailed information for clinicians ordering genetic tests can be found [here](#).

Option 2

When the diagnosis of PROS has not been considered because an individual has atypical phenotypic features, genomic testing on an appropriate sample (see above) may be considered.

Comprehensive genomic testing does not require the clinician to determine which gene is likely involved. **Exome sequencing** is most commonly used; **genome sequencing** is also possible.

For an introduction to comprehensive genomic testing click [here](#). More detailed information for clinicians ordering genomic testing can be found [here](#).

Table 1. Molecular Genetic Testing Used in *PIK3CA*-Related Overgrowth Spectrum

Gene ¹	Method	Proportion of Probands with a Pathogenic Variant ² Detectable by Method
<i>PIK3CA</i>	Sequence analysis ^{3, 4}	100% ⁵
	Gene-targeted deletion/duplication analysis ⁶	None reported ⁷

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include missense, nonsense, and splice site variants and small intragenic deletions/insertions; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click [here](#).

4. The choice of method for somatic *PIK3CA* variant detection (see Molecular Genetics) depends on several factors. Several manufacturers have developed PCR-based assays for detection of specific *PIK3CA* variants commonly found in cancers, and many of these variants have also been found in individuals with PROS as well. The data suggest that while there are mutational hot spots (e.g., *PIK3CA* codons 542, 545, and 1047), there are a substantial number of rare pathogenic variants.

5. Because most affected individuals have a somatic mosaic *PIK3CA* pathogenic variant, the actual detection rate depends on the type of sample provided and the molecular genetic testing method used.

6. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

7. The pathogenic variants observed in PROS have all been associated with gain of function; thus, partial or whole *PIK3CA* deletions and duplications are not likely to lead to this phenotype.

Clinical Characteristics

Clinical Description

PIK3CA-related overgrowth spectrum (PROS) includes overgrowth of a broad range of tissues that may or may not be accompanied by cellular dysplasia. Prior to the understanding of the molecular nature of PROS, a number of distinct but overlapping phenotypes were clinically described and given names (see *GeneReview* Scope).

In general, PROS can be divided into an **isolated** form (when a person has a focal lesion that affects only one tissue or body part; see Table 2) and a **syndromic** form (i.e., overgrowth plus at least two other features in two systems; see Table 3). A targeted therapy aimed at inhibiting PI3K-related pathway overgrowth has been approved by the FDA (see Table 6).

Table 2. Selected Isolated *PIK3CA*-Related Overgrowth Phenotypes by Affected Organ or Tissue

Organ or Tissue	Phenotype	Comment
Brain/Head	HMEG: brain overgrowth affecting 1 hemisphere w/or w/o cortical dysplasia	<ul style="list-style-type: none"> Cognitive & developmental disabilities Seizures are common. Focal neurologic deficits may be present. May result in facial asymmetry
	Focal cortical dysplasia ¹	<ul style="list-style-type: none"> Types I, II, III ² Overgrowth not as exaggerated as in HMEG May → epilepsy, which may be refractory to medications if childhood onset Cognitive impairment
	DMEG: focal brain overgrowth w/cortical dysplasia; cortical dysplasia may be bilateral.	<ul style="list-style-type: none"> Developmental delay Frequently severe epilepsy ³ w/in 1st few mos of life Focal neurologic deficits may be present.
	Facial infiltrating lipomatosis	<ul style="list-style-type: none"> Unilateral hypertrophy of soft tissues of the face (most commonly cheek) w/underlying fat infiltration ^{4, 5} May incl bony hypertrophy
Limb	Hemihyperplasia	<ul style="list-style-type: none"> May incl whole limb, part of limb, or only hand or foot (acral overgrowth) May involve soft tissue, muscle, &/or bone
	Macroductyly	<ul style="list-style-type: none"> May affect ≥1 digits on hand or foot May involve soft tissue, muscle &/or bone
	Fibroadipose vascular anomaly	<ul style="list-style-type: none"> Fibrofatty tissue w/dilated veins (phlebectasia) replaces muscle fibers. Low-flow venous or lymphatic malformation ⁶ May present as painful lump, typically of the gastrocnemius May be assoc w/ankle dorsiflexion & calf contracture
	Macroductyly or macrodystrophia lipomatoma	<ul style="list-style-type: none"> Fibroadipose tissue enlargement & bony overgrowth w/in a nerve territory (e.g., upper or lower limbs, hands & feet) w/↑ length & circumference of peripheral nerve Growth can be static (proportionate) or progressive (disproportionate).
Lymphatics ⁷	Isolated lymphatic malformations: dilated vascular channels lined by lymphatic endothelial cells	Fluid-filled cysts usually grow proportionally w/growth of affected person; may → pain &/or morbidity if they are infiltrative.
Vascular ⁷	Vascular malformations	Incl capillary, venous, or mixed malformations

Table 2. continued from previous page.

Organ or Tissue	Phenotype	Comment
Skin	<ul style="list-style-type: none"> • Benign lichenoid keratosis • Epidermal nevi • Seborrhic keratosis 	Skin lesions are typically benign.

Overgrowth can affect any part of the body depending on the distribution of the *PIK3CA* pathogenic variant in various tissues and organs.

DMEG = dysplastic megalencephaly; HMEG = hemimegalencephaly

1. Often characterized histologically as having dysplastic neurons, balloon cells, and lamination disorganization

2. Type I: isolated focal lesions with architectural abnormalities

Type II: isolated focal lesions with architectural and dysmorphic abnormalities

Type III: cortical disorganization associated with or adjacent to other principal lesions

3. Seizures are typically partial and may include infantile spasms, tonic seizures, or electroclinical features of Ohtahara syndrome.

4. May be associated with precocious dental development, macrodontia, hemimacroglossia, protuberances on the tongue and buccal mucosa, and mucosal neuromas

5. Couto et al [2017]

6. Rare high-flow variants due to excessively muscularized venous channels. Organizing thrombi may be present.

7. Overgrowth of capillary, lymphatic, and venous channels is sometimes referred to as CLVM (capillary lymphatic venous malformations), in which dilated lymphatic channels are combined with venous and capillary components.

Table 3. Selected Syndromic *PIK3CA*-Related Overgrowth Phenotypes

Phenotype ¹	Types of Overgrowth	Malformations/Abnormalities			
		Cutaneous & vascular	Musculoskeletal	Visceral	Neurologic
CLOVES (See Figure 1.)	<ul style="list-style-type: none"> • Asymmetric • Congenital lipomatous overgrowth of limb or on trunk • Hand &/or foot • Plantar-palmar overgrowth 	<ul style="list-style-type: none"> • Typically lymphatic low flow in areas of overgrowth • Linear EN • Morbid paraspinal high-flow lesions & phlebectasia 	<ul style="list-style-type: none"> • Scoliosis • Spina bifida • Pectus deformities • Sandal-gap toes • Splayed feet & toes • Macro-, poly-, & syndactyly • Chondromalacia patellae • Dislocated knees 	<ul style="list-style-type: none"> • Renal agenesis/hypoplasia • Splenic lesions • Wilms tumor 	<ul style="list-style-type: none"> • HMEG • Seizures
CLAPO	Partial/generalized of soft tissues & bone	<ul style="list-style-type: none"> • Lower-lip capillary malformation w/o progression • Lymphatic malformation of face/neck & upper body 			

Table 3. continued from previous page.

Phenotype ¹	Types of Overgrowth	Malformations/Abnormalities			
		Cutaneous & vascular	Musculoskeletal	Visceral	Neurologic
FH or FAO	<ul style="list-style-type: none"> Segmental & progressive overgrowth of subcutaneous & visceral fibroadipose tissue Occasional skeletal overgrowth Disproportionate linear overgrowth 	<ul style="list-style-type: none"> Vascular malformation EN 	<ul style="list-style-type: none"> Progressive skeletal overgrowth (preserved architecture) Polydactyly Lipomatous infiltration of muscle 	<ul style="list-style-type: none"> Testicular or epididymal cysts & hydrocele Non-spleen/thymus visceral overgrowth 	
HHML	<ul style="list-style-type: none"> Asymmetric overgrowth of a body part or body segment Overgrowth may be static or mildly progressive. 	Multiple lipomas			
KTS	Bone &/or soft tissue overgrowth in a unilateral limb	<ul style="list-style-type: none"> Low-flow venous or lymphatic malformations Port-wine nevus (capillary malformations) 	Digital enlargement		
MCAP or M-CM (See Figures 2, 3.)	<ul style="list-style-type: none"> Megalencephaly & HMEG ² Generalized overgrowth (macrosomia) 	Cutaneous vascular malformations, esp cutis marmorata & capillary malformations of the face	<ul style="list-style-type: none"> Cutaneous syndactyly & postaxial polydactyly or polysyndactyly Subcutaneous lipomas 	Wilms tumor (rare)	<ul style="list-style-type: none"> Hypotonia Seizures Autistic features Mild-to-severe ID Behavioral problems Meningioma-assoc symptoms (rare)

Table 3. continued from previous page.

Phenotype ¹	Types of Overgrowth	Malformations/Abnormalities			
		Cutaneous & vascular	Musculoskeletal	Visceral	Neurologic
MPPH ³	Brain overgrowth ⁴		<ul style="list-style-type: none"> • Syndactyly • Depressed nasal bridge 		<ul style="list-style-type: none"> • DD • ID • Hypotonia • Seizures • Medulloblastoma- assoc clinical features (very rare)

CLAPO = capillary malformation of the lower lip, lymphatic malformation of the face and neck, asymmetry and partial/generalized overgrowth; CLOVES = congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal; DD = developmental delay; EN = epidermal nevi; FH or FAO = fibroadipose hyperplasia or overgrowth; HHML = hemihyperplasia multiple lipomatosis; HMEG = hemimegalencephaly; ID = intellectual disability; KTS = Klippel-Trenaunay syndrome; MCAP or M-CM = megalencephaly-capillary malformation; MPPH = megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome

1. Most common findings; see text for more information.

2. May also include cortical dysplasia, polymicrogyria, Arnold-Chiari malformation, and ventriculomegaly

3. Individuals with this phenotype may also display dysmorphic features including prominent forehead, widely spaced eyes, downslanted palpebral fissures, low-set ears, preauricular pits, anteverted nares, and a high and narrow palate.

4. May include megalencephaly, hydrocephalus, and polymicrogyria




Figure 1. Features of CLOVES syndrome in a child with (A) a large lipomatous truncal mass that extends into the surrounding tissues and an overlying capillary malformation and (B) macrodactyly of the left foot



Figure 2. Features of MCAP syndrome. Photographs of an individual with MCAP syndrome demonstrating the apparent macrocephaly with prominent forehead (D); extensive capillary malformations (A-F1); bilateral 2-3-4 toe syndactyly (G, H); 3-4 finger syndactyly (F1, F2); and postaxial polydactyly of the right hand (F1)

From Mirzaa et al [2012]. Used by permission.



Figure 3. Features of MCAP syndrome. A boy age 40 months with MCAP syndrome (left) and his unaffected twin sister (right). Note left-sided hemihypertrophy, typical facial features, bilateral 2-3 toe syndactyly, and connective tissue dysplasia with loose redundant skin.

From Conway et al [2007b]. Used by permission.

Overgrowth

PIK3CA pathogenic gain-of-function variants can cause overgrowth of almost any type of tissue. Onset of overgrowth is typically congenital or early postnatal, in contrast to onset in later infancy or childhood.

The predominant areas of involvement include the brain, limbs (including fingers and toes), trunk (including abdomen and chest), and face, all usually in an asymmetric distribution.

Overgrown tissue may have a "ballooning" appearance - that is, the involved body part (usually finger/s, toe/s, and/or dorsum of the hand or foot) resembles an inflated balloon.

Unilateral involvement is more common than bilateral involvement.

Overgrowth may include some or all of the following tissue types:

- Fibrous, including dense fibrous tissue encircling the nerves in individuals with the fibroadipose vascular anomaly (See Table 2.)
- Nervous (See Brain Growth.)
- Vascular (See Vascular Malformations.)
- Lymphatic (See Lymphatic Malformations.)
- Skeletal (See Skeletal Findings.)
- Lipomatous (See Lipomatous Overgrowth with or without Regional Reduction of Adipose Tissue.)

Brain Growth

Generalized brain overgrowth may be accompanied by secondary overgrowth of specific brain structures resulting in ventriculomegaly, a markedly thick corpus callosum, and cerebellar tonsillar ectopia with crowding of the posterior fossa [Conway et al 2007b, Mirzaa et al 2012]. Adult OFCs range from +2 to as large as +10 SDs above the mean.

Megalencephalopathy. Although most affected individuals have macrocephaly due to megalencephaly (MEG) at birth, a few affected individuals have normal head size at birth but develop progressive macrocephaly due to progressive MEG within the first year of life [Moore et al 1997, Conway et al 2007a, Conway et al 2007b, Mirzaa et al 2012].

In children who have undergone neurosurgical shunting for obstructive ventriculomegaly or hydrocephalus, head growth noticeably continues at an accelerated pace, indicating the primary nature of MEG in individuals who have MEG as part of their PROS findings.

MCAP syndrome. In a review of 21 children, birth occipitofrontal circumference (OFC) typically ranged from +2 to +7 SDs above the mean for gestational age [Mirzaa et al 2012; Author, unpublished data].

In most children, OFC SD increased during the first year of life. Although head growth may level off in early childhood, it typically remains at +3 SD or more above the mean.

Vascular Malformations

Vascular malformations may include capillary, venous, and less frequently, arterial or mixed (capillary-lymphatic-venous or arteriovenous) malformations. Low-flow vascular malformations (lymphatic, venous) may be found overlying truncal or limb overgrowth. Vascular malformations may be superficial or deep (visceral). Many of these lesions can only be identified by MRA/MRV imaging (see [ISSVA Classification for Vascular Anomalies - 2018](#)).

- Cutaneous **capillary malformations** may be midline on the face (persistent nevus simplex) or widespread on the entire body having a reticulated appearance similar to cutis marmorata.
- **Venous malformations** (VM), including aneurysms, are characterized by enlarged and distorted blood vessel channels, which may grow over time and cause significant morbidity, including bleeding, pain and disfigurement.
- Affected individuals may be at increased risk for deep venous thrombosis and pulmonary embolism, especially those with **combined capillary-lymphatic-venous malformations** [Douzgou et al 2022].
 - The risk increases after surgery or sclerotherapy.
 - Thrombotic risk may also be increased due to other causes of chronic stasis including impaired mobility (e.g., dehydration, surgery), decreased anticoagulant proteins, and the effect of the specific pathogenic *PIK3CA* variant on the vascular endothelium [Keppler-Noreuil et al 2019].
- High-flow vascular malformations (arteriovenous) can also occur, especially involving the spinal-paraspinal areas.
- Individuals with the Klippel-Trenaunay phenotype can have hemangiomas and venous and/or lymphatic malformations and are at risk for Kasabach-Merritt syndrome, characterized by thrombocytopenia and coagulopathy.

Lymphatic Malformations

Lymphatic malformations may be in various locations (internal and/or external) and can cause various clinical issues including swelling, pain, and occasionally localized bleeding secondary to trauma. Some individuals may have complicated lymphatic anomalies, especially generalized lymphatic anomaly [Rodriguez-Laguna et al 2019]. Complex lymphatic anomalies can have an aggressive course, are difficult to treat, and have a poor prognosis, especially when located in close proximity to vital structures of the anterior head and neck region.

Skeletal Findings

Characteristic findings in the hands include broad, spade-like hands with splayed or ulnar deviation of the fingers and overgrowth of one or more fingers.

Characteristic findings in the feet include overgrowth with a large "sandal" gap between the great and second toes, large bulbous toes, lipomatous masses on both the dorsal and plantar surfaces, or broad forefoot with wide gaps between the metatarsal heads.

Patterning defects may include postaxial, preaxial, or central polydactyly and cutaneous syndactyly, which often involves the toes, but can include the fingers. The cutaneous syndactyly occurs in patterns of 2-3 toes, 2-4 toes, and 2-5 toes with sandal-gap toes.

Dislocated knees, leg-length discrepancy, and pattern chondromalacia can occur.

Some affected individuals may have scoliosis, vertebral anomalies, spina bifida, and/or pectus anomalies, particularly in the CLOVES phenotype.

Progressive skeletal overgrowth has been described in those with the FH or FAO phenotype.

Individuals with the MCAP phenotype may have joint hypermobility due to connective tissue dysplasia.

Lipomatous Overgrowth with or without Regional Reduction of Adipose Tissue

Lipomatous overgrowth may occur ipsilateral or contralateral to a vascular malformation, if present. The characteristic truncal lipomatous mass infiltrates surrounding tissues and often requires surgical excision. Severe scoliosis, large truncal mass, paraspinal high-flow lesions with spinal cord ischemia, lymphatic malformations, cutaneous vesicles, orthopedic problems of the feet and hands, and central phlebectasia/thromboembolism are examples of significant morbidities that need active or prophylactic medical intervention (see Management).

- Paraspinal and intraspinal extension, more commonly seen in individuals with the CLOVES phenotype, present significant risk for compression of the cord, thecal sac, and nerve roots, with resultant major neurologic deficits including myelopathy, warranting prompt diagnosis and multidisciplinary care [Alomari 2009].
- Lipomatosis can be invasive, invading hip joints and intravertebral spaces, which can become quite painful.
- Infiltration of adipose tissue into muscle with either replacement or compression of muscle, as well as into viscera (liver, spleen, pancreas), intestines, mediastinum, and spine has also been described.
- Surgery can be difficult because of the vascularity of the lipomatous tissue and the risk of thrombosis.
- *PIK3CA* pathogenic gain-of-function variants can cause regional reduction of adipose tissue that is often accompanied by significant overgrowth in another part of the body. For example, reduction of adipose tissue in the upper limbs, chest, or upper abdomen has been observed in those with significant overgrowth in the lower body or lower limbs/feet.

Developmental Delay and Intellectual Disability

The degree of intellectual disability (ID) appears to be mostly related to the presence and severity of seizures, cortical dysplasia (e.g., polymicrogyria), and hydrocephalus (see Neuroimaging). Gross motor delays are probably attributable to multiple factors in the affected individual including the presence of MEG, cortical brain malformations, hypotonia, limb asymmetry or overgrowth, and connective tissue dysplasia.

MCAP syndrome

- Most individuals with MCAP syndrome have some intellectual disability; the degree is variable and ranges from mild learning disability to severe disability.
- Most have mild-moderate delays yet continue to make steady developmental progress, albeit at a slower rate.
- A few (<10%) have severe handicaps. The range of expected milestone acquisition has not yet been clarified in individuals with MCAP syndrome.

Other Neurodevelopmental Features

Hypotonia. Younger children with polymicrogyria (specifically of the frontal region) have hypotonia, are not spastic, and may have pseudobulbar problems; older children often have spasticity and pseudobulbar problems [Mirzaa et al 2012].

Infant feeding difficulties. Many children may have feeding difficulties that are often multifactorial in nature (e.g., due to hypotonia, GERD), although use of a feeding tube is rarely required.

Epilepsy. An estimated 30%-40% of individuals with *PIK3CA* pathogenic variants have epilepsy. Reported seizure types include focal and tonic-clonic (among others), though seizure types, severity, age of onset, and any associated EEG or neuroimaging abnormalities depend primarily on the tissue distribution of the pathogenic *PIK3CA* variants and the presence or absence of associated cortical malformations.

Symptoms of cerebellar tonsillar ectopia (Chiari malformation). Infants may have irritability, excessive drooling, difficulty swallowing, or breathing problems, especially central apnea. Children may have neck pain or headache, motor weakness, sensory changes, vision problems, swallowing difficulties, or behavioral changes.

Behavioral Issues and Autistic Features

A subset of children (6/21) with MCAP syndrome have autistic features or a clinical diagnosis of autism [Mirzaa et al 2012], suggesting that autism may be part of the neurocognitive profile of a minority of individuals who

have MEG as part of PROS [McBride et al 2010]. Other behavioral abnormalities seen in one or a few affected individuals:

- Attention-deficit/hyperactivity disorder
- Obsessive-compulsive tendencies
- Anxiety-related issues

Neuroimaging

Individuals with PROS who have macrocephaly typically undergo brain imaging shortly after birth or within the first year of life, leading to early identification of the following key neuroimaging features (see Figure 4) [Vogels et al 1998, Nyberg et al 2005, Conway et al 2007a, Conway et al 2007b, Martínez-Lage et al 2010, Mirzaa et al 2012].

Megalencephaly [Clayton-Smith et al 1997, Vogels et al 1998, Robertson et al 2000, Nyberg et al 2005, Coste et al 2012]. In some instances, MEG (with or without ventriculomegaly) is detected prenatally on ultrasound examination, along with a thickened corpus callosum. More than 90% of affected individuals have congenital MEG that is universally progressive.

Ventriculomegaly and hydrocephalus. Most affected children have evidence of ventricular dilatation or ventriculomegaly on early brain imaging:

- In a large review of the neuroimaging findings in individuals with MCAP syndrome, 37 (56%) of 65 children had ventriculomegaly ranging from mild-to-frank hydrocephalus, with or without cerebellar tonsillar ectopia [Conway et al 2007b].
- While it is unclear whether ventriculomegaly is obstructive in all these individuals, more than half of affected children undergo ventricular shunting or third ventriculostomy, usually within the first year of life.

Cerebellar tonsillar ectopia (CBTE). A large cerebellum combined with a small posterior fossa leading to cerebellar tonsillar ectopia (Chiari malformation) and syringomyelia are common complications, particularly in those with MCAP syndrome:

- Fifteen of 65 reported affected individuals with MCAP have evidence of CBTE with or without herniation [Conway et al 2007b].
- The degree of ectopia is best objectively assessed by measuring the distance of the cerebellar tonsils below the foramen magnum.
- Unlike ventriculomegaly, CBTE is rarely congenital in individuals with MCAP syndrome.
- In two individuals spontaneous "resolution" of CBTE on follow-up imaging was attributed to disproportionately accelerated skull overgrowth [Mirzaa et al 2012].

Cortical brain malformation and polymicrogyria (PMG). PMG may be present in more than 50% of affected children, most commonly those with the MCAP phenotype [Conway et al 2007b; Gripp et al 2009; Mirzaa et al 2012; Authors, unpublished data].

- The most common type of PMG in those with MCAP syndrome is bilateral perisylvian PMG, although other types including bilateral frontal and focal PMG occur.
- PMG broadly, and bilateral perisylvian PMG in particular, increase the risk for: epilepsy; oral motor weakness leading to feeding, swallowing, and expressive language difficulties; developmental delay; and tone abnormalities.




Figure 4. Characteristic brain MRI of MCAP syndrome in three individuals (A-D, E-H, and I-L). Note: Megalecephaly with a prominent forehead (A, E, I); cerebellar tonsillar ectopia with a large cerebellum and crowded posterior fossa (A, E, I); ventriculomegaly (G) and hydrocephalus (J, K, L); and bilateral perisylvian polymicrogyria (B, D, F, G, H, K, and L).

From Mirzaa et al [2012]. Used by permission.

Tumors

Benign tumors. The most common are vascular, described variably as (cavernous) hemangiomas, angiomas, angiomyolipomas, and vascular masses [Clayton-Smith et al 1997, Moore et al 1997, Martínez-Glez et al 2010].

- Cavernous hemangiomas have occurred in brain tissue, necessitating debulking when they enlarge and cause pain.
- While most common in skin or subcutaneous tissue, hemangiomas have been described in viscera and skull.

Other benign tumors have included two individuals with MCAP (ages 21 months and 5 years) who had meningioma (which do not tend to enlarge, spread, or metastasize); two individuals with PROS who had spinal and major nerve neurofibromas; and several others with ovarian cystadenoma, uterine fibroids, and lipomas [Keppler-Noreuil et al 2014].

Malignant tumors. If present, most affected individuals have benign tumors, with only a few malignant tumors reported [Kurek et al 2012, Keppler-Noreuil et al 2014, Luks et al 2015, Gripp et al 2016, Huchtagowder et al 2017, Kuentz et al 2017, Peterman et al 2017, Postema et al 2017].

The estimated frequency of Wilms tumor ranges from 1.4% to 3.3%. Of 12 individuals reported to have Wilms tumor or nephroblastomatosis, clinical PROS diagnoses included CLOVES (8 individuals), MCAP (2 individuals), and KTS (2 individuals).

- Mean age at diagnosis was 27.4 months (median 18 months; range 9-119 months).
- Tumor type included seven individuals (~60%) with Wilms tumor, four (33%) with indeterminate features of Wilms tumor vs nephroblastomatosis, and one (8%) with nephroblastomatosis.
- Six (50%) had somatic "hot spot" *PIK3CA* variants (see Molecular Genetics).

There have been several case reports of individuals with PROS who developed other cancers including the following [Moore et al 1997, Schwartz et al 2002, Mills et al 2018]:

- Leukemia (in those with the MCAP phenotype)
- Vestibular schwannoma
- Retinoblastoma

Systematic data are at present insufficient to determine whether there is a true association between PROS and the development of these types of tumors or whether the case reports represent rare co-occurrences of PROS with these tumors.

Other

Kidney. Kidney malformations are frequently found in individuals with PROS, and more specifically the CLOVES phenotype, and include pelviectasis, dilated ureters, hydronephrosis, duplicated renal arteries, renal cysts, and enlarged kidneys.

Skin. Abnormalities observed in PROS:

- Dermal melanocytic nevi
- Café au lait macules
- Hypopigmented macules
- Cutis marmorata
- Pigmented nevi
- Patchy hyperpigmentation that follows the lines of Blaschko
- Linear keratinocytic epidermal nevi, which may occur anywhere on the body and may follow a dermatomal distribution
- Seborrheic keratosis and benign lichenoid dermatosis
- Skin hyperelasticity, laxity, and thick subcutaneous tissue in those with the MCAP phenotype due to connective tissue dysplasia

Endocrine issues affect a small number of individuals and most commonly include hypoglycemia (largely hypoinsulinemic hypoketotic hypoglycemia), growth hormone deficiency, and hypothyroidism [Mirzaa et al 2016, Leiter et al 2017, Davis et al 2020, Maines et al 2021, Douzgou et al 2022].

- PROS is a clinical phenocopy of congenital hyperinsulinism (see Molecular Genetics), but plasma insulin concentrations at the time of hypoglycemia are undetectable.
- This profile has been reported both in individuals with MCAP and in those with overlapping forms of PROS that include brain involvement.

- While hypoglycemia in PROS is most commonly diagnosed in the neonatal period, some individuals may present later in childhood, including at least one male with MCAP who presented with his first episode of hypoglycemia at age six years [Author, personal communication].
- Hypoglycemia may be persistent over time, requiring consistent glucose monitoring, evaluation of the hypothalamic-pituitary-adrenal axis, and ongoing treatment (see Management).

Cardiac issues. Structural heart defects (e.g., atrial and ventricular septal defects) and/or abnormalities of the great vessels have been reported in some individuals with MCAP syndrome [Mirzaa et al 2016].

Genotype-Phenotype Correlations

There are several mutational hot spots in *PIK3CA* (see Molecular Genetics and Table 9) that are more commonly associated with highly focal phenotypes (CLOVES syndrome, fibroadipose hyperplasia, lymphatic/vascular malformations, hemimegalencephaly and focal cortical dysplasia), namely: p.Glu542Lys, p.Glu545Lys, p.His1047Arg, p.His1047Lys [Mirzaa et al 2016]. These mutational hot spots, when present in the brain, are associated with more severe epilepsy phenotypes as well [Pirozzi et al, in press]. The same *PIK3CA* missense variants may be found in individuals with PROS and in unaffected individuals with *PIK3CA*-related cancer (Tables 8 and 9).

Further, analysis of individuals with PROS suggests that MCAP syndrome in particular is primarily associated with a wide range of *PIK3CA* variants that are widely distributed across the gene, and less likely associated with *PIK3CA* mutational hot spots [Mirzaa et al 2016] (see Molecular Pathogenesis).

Nomenclature

Due to the phenotypic variability of the disorders caused by somatic *PIK3CA* pathogenic variants, researchers at an NIH Workshop in 2013 proposed the umbrella term *PIK3CA*-related overgrowth spectrum [Keppler-Noreuil et al 2015]. The *PIK3CA*-related overgrowth spectrum encompasses all the unique, clinically defined entities but highlights the continuum and overlap between the phenotype diagnoses.

Prevalence

The prevalence of *PIK3CA*-related overgrowth spectrum (PROS) is difficult to estimate due to variation in ascertainment and the broad phenotypic spectrum. More than 200 individuals with MCAP syndrome have been reported.

Genetically Related (Allelic) Disorders

No phenotypes other than those discussed in this *GeneReview* are known to be associated with germline pathogenic variants in *PIK3CA*.

Sporadic tumors (including breast, colon, uterine, and others) occurring as single tumors in the absence of any other findings of PROS frequently contain a somatic variant in *PIK3CA* that is **not** present in the germline. For more information, see Cancer and Benign Tumors.

Differential Diagnosis

A number of overgrowth and megalencephaly disorders overlap with the *PIK3CA*-related overgrowth spectrum (PROS), including those summarized in Table 4.

Table 4. Genes of Interest in the Differential Diagnosis of *PIK3CA*-Related Overgrowth Spectrum (PROS)

Gene(s)	DiffDx Disorder	MOI	Clinical Features of DiffDx Disorder	
			Overlapping w/PROS	Differentiating from PROS
<i>AKT1</i>	Proteus syndrome	NA (somatic)	Focal somatic overgrowth, epidermal nevi, vascular malformations, dysplastic adipose tissue	Cerebriform connective tissue nevi & postnatal onset of overgrowth (vs congenital onset in PROS). Absence of characteristic truncal fatty-vascular mass, spinal paraspinous fast-flow lesions, acral abnormalities of CLOVES syndrome
<i>AKT3</i> <i>CCND2</i> <i>PIK3R2</i>	Megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndrome	AD (<i>de novo</i>) or somatic	Brain overgrowth (MEG), polymicrogyria, hydrocephalus, polydactyly, connective tissue or joint laxity	Absence of consistent vascular/lymphatic malformations or severe focal somatic overgrowth
<i>HRAS</i> <i>KRAS</i> <i>NRAS</i>	Linear nevus sebaceous syndrome (LNSS) (OMIM 163200)	NA (somatic)	Cutaneous findings (incl epidermal nevi & vascular malformations)	Absence of significant tissue overgrowth or more widespread vascular/lymphatic malformations
<i>MTOR</i>	Smith-Kingsmore syndrome (SKS) (OMIM 616638)	AD (<i>de novo</i>) or somatic	Brain overgrowth (MEG), polymicrogyria, cutaneous findings (incl hyperpigmented nevi)	Absence of consistent vascular/lymphatic malformations
<i>PTCH1</i> <i>SUFU</i>	Basal cell nevus syndrome	AD	Brain overgrowth (MEG), polydactyly, syndactyly	Calcine calcification, BCCs, jaw cysts, epidermal cysts, wide ribs, many other skeletal & other multisystem features
<i>PTEN</i>	<i>PTEN</i> hamartoma tumor syndrome (PHTS)	AD	Brain overgrowth (MEG), vascular malformations (incl capillary malformations), lipomas	Intestinal hamartomas, pigmented macules of the penis, absence of significant focal somatic overgrowth, acral deformities, ↑ cancer risk of specific cancer types
	SOLAMEN syndrome (phenotypic subtype of PHTS)	See footnote 1.	Segmental overgrowth, lipomatosis, arteriovenous malformation, epidermal nevi	↑ cancer risk (ovarian cystadenoma, multiple breast tumors, thyroid adenomas), fibrocystic breast disease, gingival papules, multinodular goiter
<i>TSC1</i> <i>TSC2</i>	Tuberous sclerosis complex (TSC)	AD	Brain overgrowth (MEG, HMEG, FCD)	Absence of striking focal overgrowth & consistent vascular/lymphatic malformations; presence of white nevi, shagreen patches, ↑ multisystem cancer risk

AD = autosomal dominant; AR = autosomal recessive; CLOVES syndrome = congenital lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal and spinal syndrome; DD = developmental delay; DiffDx = differential diagnosis; FCD = focal cortical dysplasia; HMEG = hemimegalencephaly; MEG = megalencephaly; MOI = mode of inheritance; NA = not applicable; PMG = polymicrogyria; XL = X-linked

1. SOLAMEN syndrome is the consequence of a germline pathogenic variant in *PTEN* with a somatic mosaic second *PTEN* variant that gives the phenotype its segmental attributes.

Management

Clinical practice guidelines for *PIK3CA*-related overgrowth spectrum have been published [Douzougou et al 2022] (full text). Additionally, a targeted pharmacologic therapy has been FDA approved (see Table 6).

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual with *PIK3CA*-related overgrowth spectrum (PROS), the evaluations summarized in Table 5 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

Note: Assessment is complicated by variable findings in individuals with this condition. Accurate and thorough assessment of medical history is necessary to evaluate for vascular malformations as well as other clinical features.

Table 5. Recommended Evaluations Following Initial Diagnosis in Individuals with *PIK3CA*-Related Overgrowth Spectrum

System/Concern	Evaluation	Comment
Constitutional (overgrowth)	Measure growth parameters incl head circumference, total body length, length of arms, hands, legs & feet.	To assess for generalized & segmental overgrowth (incl leg length discrepancy) & macrocephaly
	Consider whole-body MRI.	In those w/truncal overgrowth
	Consider limb x-rays & subsequent limb MRI.	In those w/segmental or generalized overgrowth of a limb
	Consider spinal ultrasound in infants & spinal MRI (w/MR angiography) in older persons.	In those w/evidence of spinal involvement (See also Cardiovascular/Vascular in this table.)
	Clinical assessment for pain & functional impairment	
Constitutional (undergrowth or generalized growth restriction)	Measurement of IGF1 & IGFBP3	If low, consider referral to endocrinologist & possible assessment for GHD.
Neurologic	Neurologic eval	<ul style="list-style-type: none"> Brain MRI in those w/megalencephaly to assess for cortical malformations, ventriculomegaly/hydrocephalus, & Chiari malformation (See Surveillance.) Consider EEG if seizures are a concern.
Development	Developmental assessment	<ul style="list-style-type: none"> To incl motor, adaptive, cognitive, & speech-language eval Eval for early intervention / special education
Psychiatric/ Behavioral	Neuropsychiatric eval	Persons age >12 mos: screen for behavior concerns incl sleep disturbances, ADHD, anxiety, &/or findings suggestive of ASD.
Musculoskeletal	Orthopedics / physical medicine & rehab / PT/OT eval	<p>To incl assessment of:</p> <ul style="list-style-type: none"> Overgrowth of a limb or portion of a limb, foot abnormalities, splayed toes & spine abnormalities (incl spinal curvature) Gross motor & fine motor skills Mobility, activities of daily living, & need for adaptive devices Need for PT (to improve gross motor skills) &/or OT (to improve fine motor skills)
Gastrointestinal	Abdominal exam for organomegaly & abdominal masses	Consider imaging, incl ultrasound &/or MRI of the abdomen.

Table 5. continued from previous page.

System/Concern	Evaluation	Comment
Cardiovascular/ Vascular	Physical exam focused on external vascular malformations, recording distribution & likely type	Consider Doppler ultrasound of main vessels in arms &/or legs if vascular malformations involve the extremities; if found, consider further MRI w/& w/o MRA.
	MRI & MRA of the spine	To assess for possible high-glow spinal & paraspinal vascular lesions
	EKG & echocardiography	To assess for arrhythmias, congenital heart defects, &/or abnormalities of great vessels as clinically indicated & for those w/MCAP phenotype
Lymphatic/ Lipomatous	Physical exam for asymmetric or atypical edema or lipomas, esp around hips & spine	Consider Doppler ultrasound in infants &/or MRI/MRA/MRV scan in older persons.
Genitourinary	Renal ultrasound	To assess for Wilms tumor &/or renal malformations &/or hydronephrosis
Integument	Full skin eval	For evidence of vascular malformations & pigmentary anomalies
Endocrine	Measurement of glucose levels in infants & children ¹	To assess for evidence of hypoglycemia
	Measurement of IGF1 & IGFBP3	Indirect assessment for GHD in those w/growth restriction or poor linear growth
	TSH & free T4	To assess for hypothyroidism
Hematologic	Hematology consult for recommendations for baseline eval	<ul style="list-style-type: none"> To assess for evidence of ↑ risk of thrombosis (esp in those w/venous malformations) & coagulopathy D-dimer & fibrinogen levels may be a useful screen for thrombosis in those w/vascular malformations.
Infectious	Assessment for infections	Prophylactic antibiotics in those w/lymphovascular malformations may be considered; per vascular surgeon & interventional radiology vascular specialists
Genetic counseling	By genetics professionals ²	To inform affected persons & their families re nature, MOI, & implications of PROS in order to facilitate medical & personal decision making
Family support & resources		Assess need for: <ul style="list-style-type: none"> Community or online resources such as Parent to Parent; Social work involvement for parental support; Home nursing referral.

ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; EEG = electroencephalogram; GHD = growth hormone deficiency; IGF1 = insulin-like growth factor 1; IGFBP3 = insulin-like growth factor BP3; MOI = mode of inheritance; MRA = MR angiography; MRV = MR venography; OT = occupational therapy; PT = physical therapy; T4 = thyroxine; TSH = thyroid stimulation hormone

1. The first episode of hypoglycemia can occur later in childhood.

2. Medical geneticist, certified genetic counselor, certified advanced genetic nurse

Treatment of Manifestations

Targeted Therapy

In GeneReviews, a targeted therapy is one that addresses the specific underlying mechanism of disease causation (regardless of whether the therapy is significantly efficacious for one or more manifestation of the genetic condition);

would otherwise not be considered without knowledge of the underlying genetic cause of the condition; or could lead to a cure. —ED

There is no cure for *PIK3CA*-related overgrowth syndrome (PROS). Table 6 details a targeted pharmacologic treatment recently approved by the FDA.

Table 6. Targeted Treatment of *PIK3CA*-Related Overgrowth Spectrum

Treatment	Dosage	Indication	Mechanism
Alpelisib (VIJOICE®) ¹	<p>Treatment regimen in persons age 2 to <18 yrs:</p> <ul style="list-style-type: none"> Initial dose 50 mg taken orally 1x/day ² w/food In those age ≥6 yrs, dose may be ↑ to 125 mg 1x/day after 24 wks of treatment. ³ <p>Treatment regimen in persons ≥18 yrs: 250 mg taken orally 1x/day ¹ w/food</p>	The treatment of adult & pediatric patients age ≥2 yrs w/severe manifestations of PROS who require systemic therapy	PI3K inhibitor

PROS = *PIK3CA*-related overgrowth spectrum

1. This medication has been approved specifically for the reduction of overgrowth, vascular lesions, and other functional complications. To date, it is unknown whether this drug has any efficacy in treating the neurologic manifestations of PROS (as, e.g., in MCAP syndrome).

2. The tablet should be taken at approximately the same time every day

3. A dose reduction back to 50 mg/day may be considered in those with an adverse reaction on the higher dose.

Supportive Care

Supportive treatment should ideally be provided through coordinated care from a multidisciplinary team including surgeons, radiologists, geneticists, dermatologists, pathologists, and hematologist/oncologist, the latter of whom are critical for emerging medical management and coordination of the associated long-term follow up [Adams & Ricci 2019, Dekeuleneer et al 2020, Canaud et al 2021, Douzgou et al 2022].

Table 7. Supportive Treatment of Manifestations in Individuals with *PIK3CA*-Related Overgrowth Spectrum

Manifestation/Concern	Treatment	Considerations/Other
Segmental overgrowth	May require debulking surgery	If functional limitations or pain are moderate to severe
Leg length discrepancy	Standard treatment per orthopedist	May require a shoe lift if length discrepancy >2 cm
Megalencephaly/Ventriculomegaly	Standard treatment per neurosurgeon; may incl ventriculoperitoneal shunting or 3rd ventriculostomy	<ul style="list-style-type: none"> If signs & symptoms of obstructive hydrocephalus or ↑ intracranial pressure Hydrocephalus may be more successfully treated in those w/MCAP via a 3rd ventriculostomy [Author, personal observation].
Cerebellar tonsillar ectopia or Chiari malformations	Standard treatment per neurosurgeon; may incl a posterior fossa decompression	<ul style="list-style-type: none"> If signs & symptoms of cerebellar ectopia or syringomyelia ^{1, 2} Many affected persons have mild cerebellar tonsillar ectopia that may only require monitoring (see Surveillance).

Table 7. continued from previous page.

Manifestation/Concern	Treatment	Considerations/Other
Epilepsy ³	Standardized treatment w/ASM by experienced neurologist or epileptologist	<ul style="list-style-type: none"> Many ASMs may be effective; none has been demonstrated effective specifically for this disorder Education of parents/caregivers⁴
	Consideration of hemispherectomy or surgical resection of the epileptic focus ⁵	In those w/focal or supportive findings by neuroimaging, EEG, or clinical semiology of the seizure disorder
DD/ID	See Developmental Delay / Intellectual Disability Management Issues.	
Psychiatric/ Behavioral	Standard treatment per psychiatrist &/or developmental pediatrician	See Social/Behavioral Concerns.
Polydactyly	Consider removal of extra digits.	Per orthopedist
Foot deformities / Splayed toes	Surgical intervention may be considered; per orthopedist	To allow for shoes & improved function
Scoliosis	Standard treatment per orthopedist	
Vascular malformations	Depending on type of vascular malformations: sclerotherapy, laser therapy, or oral medications (e.g., sirolimus)	<ul style="list-style-type: none"> See also Therapies Under Investigation. Capillary malformations seldom require mgmt; may fade w/time.
Structural heart defects / Arrhythmia	Standard treatment per cardiologist	
Lymphatic malformations	Standard treatment per vascular anomalies team	May incl careful surgical debulking or oral medications (See Therapies Under Investigation.)
Lipomas	Careful surgical debulking of infiltrative masses, typically requiring multidisciplinary mgmt ⁶	Paraspinal & intraspinal extension pose significant risk for compression of the cord, thecal sac, & nerve roots.
Renal anomalies / Hydronephrosis	Standard treatment per urologist &/or nephrologist	
Wilms tumor	Standard treatment per oncologist	
Coagulopathy or thrombosis	Standard treatment per hematologist depending on the coagulation issue; may incl anticoagulant therapy for thrombosis or fresh frozen plasma infusion for coagulopathy	Those w/CLOVES phenotype are at particular risk of developing a postoperative hypercoagulable state → thrombosis.
Pain	Evaluate for source of pain & treat underlying cause, e.g., vascular malformation, secondary effects of overgrowth (nerve impingement, compression of internal organs), or functional impairments.	
Hypothyroidism	Standard treatment per endocrinologist	More likely in those w/MCAP or other forms of PROS that incl brain involvement ⁷
Hypoglycemia	<ul style="list-style-type: none"> Depending on severity, treatment can range from infusion of IV glucose to administration of sugar-containing drinks or snacks to cornstarch therapy. In some instances of persistent hypoglycemia, glucagon injections may be considered. 	<ul style="list-style-type: none"> Primarily affects neonates, though some persons may develop hypoglycemia later in life. In severe, persistent hypoglycemia, eval of the GH axis & HPA axis is indicated.
	If hypoglycemia is due to growth hormone deficiency, consideration of GH therapy	Limited data re efficacy of GH therapy & whether it is contraindicated in this population.

Table 7. continued from previous page.

Manifestation/Concern	Treatment	Considerations/Other
Growth hormone deficiency	Consider a trial of GH therapy. ⁷	<ul style="list-style-type: none"> • Undertake careful follow up of linear growth & trajectory of overgrowth. • Delay of GH therapy until after age 2 yrs has been suggested, avoiding the major period of brain growth. • Further evidence is needed to determine relative risks & benefits of GH therapy in GH-deficient persons w/PROS.⁷
Family/Community	<ul style="list-style-type: none"> • Ensure appropriate social work involvement to connect families w/local resources, respite, & support. • Coordinate care to manage multiple subspecialty appointments, equipment, medications, & supplies. 	<ul style="list-style-type: none"> • Ongoing assessment of need for palliative care involvement &/or home nursing • Consider involvement in adaptive sports or Special Olympics.

ASM = anti-seizure medication; DD/ID = developmental delay / intellectual disability; GH = growth hormone; HPA = hypothalamic-pituitary-adrenal; OT = occupational therapy; PT = physical therapy

1. Infants may have irritability, excessive drooling, difficulty swallowing, or breathing problems, especially central apnea.

2. Children may have neck pain or headache, motor weakness, sensory changes, vision problems, swallowing difficulties, or behavioral changes.

3. The severity of epilepsy varies depending on the nature and extent of cortical malformations, type of *PIK3CA* pathogenic variant, and level of mosaicism.

4. Education of parents/caregivers regarding common seizure presentations is appropriate. For information on non-medical interventions and coping strategies for children diagnosed with epilepsy see [Epilepsy Foundation Toolbox](#).

5. Di Rocco et al [2006], Kwan et al [2008], Jansen et al [2015]

6. Alomari [2009]

7. Douzgou et al [2022]

Developmental Delay / Intellectual Disability Management Issues

The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.

Ages 0-3 years. Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs.

Ages 3-5 years. In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based; for children too medically unstable to attend, home-based services are provided.

All ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of life. Some issues to consider:

- IEP services:
 - An IEP provides specially designed instruction and related services to children who qualify.
 - IEP services will be reviewed annually to determine whether any changes are needed.

- Special education law requires that children participating in an IEP be in the least restrictive environment feasible at school and included in general education as much as possible, when and where appropriate.
- Vision and hearing consultants should be a part of the child's IEP team to support access to academic material.
- PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the affected individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.
- As a child enters the teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.
- A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.
- Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a US public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
- Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.

Motor Dysfunction

Gross motor dysfunction

- Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, hip dislocation).
- Consider use of durable medical equipment and positioning devices as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).
- For muscle tone abnormalities including hypertonia or dystonia, consider involving appropriate specialists to aid in management of baclofen, tizanidine, Botox[®], anti-parkinsonian medications, or orthopedic procedures.

Fine motor dysfunction. Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and writing.

Communication issues. Consider evaluation for alternative means of communication (e.g., [augmentative and alternative communication](#) [AAC]) for individuals who have expressive language difficulties. An AAC evaluation can be completed by a speech-language pathologist who has expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication. AAC devices can range from low-tech, such as picture exchange communication, to high-tech, such as voice-generating devices. Contrary to popular belief, AAC devices do not hinder verbal development of speech, but rather support optimal speech and language development.

Social/Behavioral Concerns

Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and typically performed one-on-one with a board-certified behavior analyst.

Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications, such as medication used to treat attention-deficit/hyperactivity disorder, when necessary.

Concerns about serious aggressive or destructive behavior can be addressed by a pediatric psychiatrist.

Surveillance

Table 8. Recommended Surveillance for Individuals with *PIK3CA*-Related Overgrowth Spectrum

System/Concern	Evaluation	Frequency
Constitutional (overgrowth & generalized growth restriction)	Measurement of growth parameters, incl head circumference, length of arms, hands, legs, ¹ & feet ²	At each visit
	<ul style="list-style-type: none"> • Ultrasound or MRI follow up in those w/truncal overgrowth ² • Radiographs of limbs in those w/overgrowth of a limb or portion of a limb • Spinal MRI in those w/scoliosis or deformities that affect the spine 	As clinically indicated
Neurologic	Serial head MRI imaging	Depending on severity of findings on initial assessment & degree of brain maturation ³
	<ul style="list-style-type: none"> • Monitor those w/seizures as clinically indicated. • Assess for new manifestations incl seizures, changes in tone, & other signs/symptoms of Chiari malformation. ^{4,5} 	At each visit
Development	Monitor developmental progress & educational needs.	
Psychiatric/Behavioral	Behavioral assessment for anxiety, attention, & aggressive or self-injurious behavior	At each visit in children, adolescents, & adults
Musculoskeletal	<ul style="list-style-type: none"> • Physical medicine, OT/PT assessment of mobility, self-help skills • Clinical assessment for scoliosis 	At each visit
	Abdominal palpation for organomegaly & abdominal masses	
Vascular & lymphatic malformations	Clinical assessment & monitoring, ideally by a vascular anomalies team ⁶	As clinically indicated
Genitourinary	Consideration of renal ultrasound	Every 3 mos until age 8 yrs ⁷
Hematologic	Hematology consultation w/recommendations for assessment for thrombosis & coagulopathy risk	After any surgical intervention, esp in those w/CLOVES phenotype &/or vascular malformations
Endocrinologic	Blood glucose monitoring; in those w/proven hypoglycemia, eval of the GH axis & HPA axis is indicated.	As clinically indicated for those w/persistent hypoglycemia, particularly those who require ongoing treatment for hypoglycemia

Table 8. continued from previous page.

System/Concern	Evaluation	Frequency
Family/ Community	Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources) & care coordination.	At each visit

GH = growth hormone; HPA = hypothalamic-pituitary-adrenal; OT = occupational therapy; PT = physical therapy

1. Including leg length discrepancy
2. If rapid growth of a specific body area is identified, consider targeted follow up, which may include other types of monitoring techniques, such as volumetric studies and angiography [Douzgou et al 2022].
3. For those with CNS overgrowth or dysplasia: brain MRI every six months until age two years and then annually until age eight years to monitor specifically for progressive hydrocephalus and Chiari malformation [Douzgou et al 2022]
4. Infants may have irritability, excessive drooling, difficulty swallowing, or breathing problems, especially central apnea.
5. Children may have neck pain or headache, motor weakness, sensory changes, vision problems, swallowing difficulties, or behavioral changes.
6. Team may include specialists in dermatology, interventional radiology, and hematology/oncology.
7. Tumor screening for Wilms tumor is controversial, given the studies that suggest a frequency of Wilms tumor of between 1.4% and 3.3%. In the US, tumor screening is often undertaken if the tumor risk is 3% or greater. Further longitudinal studies are needed to evaluate the need for Wilms tumor screening in individuals with PROS.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Some studies have demonstrated the efficacy of the mammalian target of rapamycin (mTOR) inhibitor sirolimus for lymphatic diseases [Padilla et al 2019, Zenner et al 2019]. Ongoing understanding of the PI3K/AKT/mTOR signaling pathway and the natural history of PROS will provide the basis for developing new targeted therapeutic strategies. Systemic agents under investigation for PROS target different components of the PI3K signaling pathway. These include inhibitors of mTOR, AKT, and PI3K genes:

- **Sirolimus** has been investigated in several clinical trials in individuals with complex lymphatic anomalies, vascular malformations, and overgrowth disorders [Adams et al 2016, Hammer et al 2018, Adams & Ricci 2019, Parker et al 2019, Van Damme et al 2020] (see [ClinicalTrials.gov](https://clinicaltrials.gov)), some of whom had PROS. Sirolimus is currently used in an off-label capacity to treat these disorders [Seront et al 2019, Dekeuleneer et al 2020]. Sirolimus has shown efficacy in multiple Phase II studies for individuals with complicated vascular anomalies and individuals with PROS and progressive overgrowth [Adams et al 2016, Erickson et al 2017, Hammer et al 2018, Parker et al 2019, Ricci et al 2019].
- **Miransertib**, an AKT1 inhibitor, has been studied in clinical trials for expanded access, and in Phase I/II clinical trials [Wassef et al 2015, Zampino et al 2019].

Search [ClinicalTrials.gov](https://clinicaltrials.gov) in the US and [EU Clinical Trials Register](https://clinicaltrialsregister.eu) in Europe for access to information on clinical studies for a wide range of diseases and conditions.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

PIK3CA-related overgrowth disorders (PROS) are not known to be inherited, as most identified pathogenic variants are somatic (mosaic). No confirmed vertical transmission or sib recurrence has been reported to date.

Risk to Family Members

Parents of a proband

- Parents of children with somatic mosaicism for a pathogenic variant in *PIK3CA* have not been reported to have any significant distinctive manifestations of the disorder, nor would such findings be expected given the somatic nature of these genetic alterations.
- Theoretically, a parent of a child with PROS caused by a *de novo* germline *PIK3CA* pathogenic variant may have germline mosaicism for the *PIK3CA* pathogenic variant. The theoretic risk for parental germline mosaicism is estimated to be less than 1%.

Sibs of a proband

- The risk to sibs of a proband with somatic mosaicism for a pathogenic variant in *PIK3CA* would be expected to be the same as in the general population.
- The risk to sibs of a proband with a *de novo* germline *PIK3CA* pathogenic variant is slightly greater than that of the general population because of the theoretic risk (estimated to be <1%) of parental germline mosaicism.

Offspring of a proband

- Reproductive outcome data on adults with PROS are limited; there are no instances of vertical transmission of these disorders. While adults with PROS have been reported, the developmental outcome of affected individuals is unknown. Individuals with significant neurologic involvement (e.g., DMEG, HMEG) have a poor prognosis.
- All but a few affected individuals with PROS have had somatic mosaicism for a *PIK3CA* pathogenic variant, suggesting that mutation occurred post fertilization in one cell of the multicellular embryo. Therefore, the risk for transmission to offspring is expected to be less than 50%.
- Several individuals with PROS have had a *de novo* germline pathogenic variant in *PIK3CA* [Rivière et al 2012, Mirzaa et al 2016]. The offspring of individuals with a constitutional germline *PIK3CA* pathogenic variant have a 50% risk of inheriting the pathogenic variant.

Other family members. The risk to other family members is the same as that of the general population.

Related Genetic Counseling Issues

Family planning

- Counseling for recurrence risk in PROS should emphasize that, while no pregnancy is at zero risk, all empiric evidence suggests that the risk for recurrence in sibs of a proband is not increased over that of the general population, due to the mosaic nature of most of these disorders. The rare families with PROS caused by a *de novo* germline *PIK3CA* pathogenic variant should be counseled regarding the theoretic risk for parental germline mosaicism (~<1%).
- The optimal time for determination of genetic risk is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected.

Prenatal Testing and Preimplantation Genetic Testing

Molecular genetic testing. Because vertical transmission of PROS has not been reported to date, family members are not known to be at increased risk of being affected and prenatal diagnosis and preimplantation genetic testing are usually not indicated for family members. However, low-level germline mosaicism may theoretically be present in a parent of a child with a germline *PIK3CA* pathogenic variant. Prenatal testing or preimplantation genetic testing may be an option for such rare families.

In addition, molecular genetic prenatal testing may be an option for pregnancies identified by ultrasound examination to be at risk for PROS.

- Findings on ultrasound examination that suggest MCAP syndrome include marked fetal overgrowth and progressive macrocephaly with no indication of maternal hyperglycemia or fetal hyperinsulinism. Other reported fetal ultrasound findings include ventriculomegaly, pleural effusions, polyhydramnios, hydrops, limb asymmetry, and frontal bossing [Nyberg et al 2005]. A fetal MRI in an affected fetus with megalencephaly and ventriculomegaly revealed diffuse bilateral polymicrogyria and polysyndactyly of one foot [Gripp et al 2009].
- Findings on prenatal ultrasound examination in CLOVES syndrome include prenatal overgrowth, lipomatous truncal masses, and vascular or lymphatic malformations [Sapp et al 2007, Alomari 2009, Alomari 2011].

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).

- **CLOVES Syndrome Community**

PO BOX 406

West Kennebunk 04094

Phone: 833-425-6837

Email: info@clovessyndrome.org

www.clovessyndrome.org

- **M-CM Network**

PO Box 97

Chatham NY 12037

Phone: 518-392-2150

Email: hello@m-cm.net

www.m-cm.net

- **M-CM Network Contact Registry**

The M-CM Network contact registry will be used to inform individuals with M-CM and their guardians about: opportunities to participate in research, opportunities to contribute data, and discoveries about M-CM that may impact care decisions.

[Contact Registry](#)

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A. PIK3CA-Related Overgrowth Spectrum: Genes and Databases

Gene	Chromosome Locus	Protein	Locus-Specific Databases	HGMD	ClinVar
PIK3CA	3q26.32	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	PIK3CA database	PIK3CA	PIK3CA

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click [here](#).

Table B. OMIM Entries for PIK3CA-Related Overgrowth Spectrum ([View All in OMIM](#))

155500	MACRODACTYLY
162900	NEVUS, EPIDERMAL
171834	PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, ALPHA; PIK3CA
602501	MEGALENCEPHALY-CAPILLARY MALFORMATION-POLYMICROGYRIA SYNDROME; MCAP
612918	CONGENITAL LIPOMATOUS OVERGROWTH, VASCULAR MALFORMATIONS, AND EPIDERMAL NEVI
613089	CAPILLARY MALFORMATION OF THE LOWER LIP, LYMPHATIC MALFORMATION OF FACE AND NECK, ASYMMETRY OF FACE AND LIMBS, AND PARTIAL/GENERALIZED OVERGROWTH
615108	COWDEN SYNDROME 5; CWS5

Molecular Pathogenesis

PIK3CA-related overgrowth spectrum disorders are typically caused by postzygotic somatic variants in the gene that encodes phosphatidylinositol-3-kinase (PI3K) catalytic subunit alpha (p110alpha) [Engelman et al 2006]. These variants are associated with hyperactivation of the PI3K signaling pathway, which includes multiple downstream effectors such as AKT and mTOR, resulting in abnormal growth of various tissues and vascular malformations.

The *PIK3CA* protein is critical for the action of insulin to lower blood glucose, and for the action of insulin-like growth factor 1 (IGF1), which promotes tissue growth through a receptor closely similar to the insulin receptor, and which mediates many actions of growth hormone. Pathologically activated *PIK3CA* may mimic the action of insulin and/or IGF1 in cells. For such a mechanism to translate into a clinically important endocrinopathy, target tissues need to have a high variant burden. This mechanism may explain why some affected infants have clinical features similar to hyperinsulinism.

Mechanism of disease causation. Gain of function

***PIK3CA*-specific laboratory technical considerations.** Because most affected individuals having a mosaic *PIK3CA* pathogenic variant, use of custom restriction fragment length polymorphism (RFLP) assays or digital droplet PCR on an appropriate sample may be necessary. Standard-depth exome sequencing can miss mosaic *PIK3CA* variants, especially if performed on blood-derived DNA.

- In order to detect new or very rare variants, sequencing of entire exons is typically necessary.
- Sanger sequencing can be used only if the pathogenic variant allele fraction is relatively high (~20%).

- Targeted capture of the entire *PIK3CA* coding region followed by next-generation sequencing at very deep coverage may be better suited for somatic variant detection, as it allows for detection of very low levels of mosaicism throughout the gene.
- In MCAP syndrome, sequence analysis of DNA derived from saliva or skin fibroblasts (whether visibly affected or not) has a higher detection rate than peripheral blood-derived DNA [Mirzaa et al 2016].
- In focal brain overgrowth disorders (HMEG, FCD, DMEG), analysis of DNA derived from affected brain tissues (for example, removed at the time of epilepsy surgery) has a higher detection rate than peripheral tissues (blood or saliva) [Jansen et al 2015].

Table 9. Notable *PIK3CA* Pathogenic Variants

Reference Sequences	DNA Nucleotide Change	Predicted Protein Change	Comment	Reference
NM_006218.4	c.1624G>A	p.Glu542Lys	Mutational hot spots assoc w/highly focal phenotypes & more severe epilepsy when present in the brain ¹	D’Gama et al [2015]
	c.1633G>A	p.Glu545Lys		Rivière et al [2012]
	c.3140A>G	p.His1047Arg		D’Gama et al [2015]
	c.3141T>A	p.His1047Lys		Kuentz et al [2017]

Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See [Quick Reference](#) for an explanation of nomenclature.

1. CLOVES syndrome, fibroadipose hyperplasia, lymphatic/vascular malformations, hemimegalencephaly, and focal cortical dysplasia (See Genotype-Phenotype Correlations.)

Cancer and Benign Tumors

PIK3CA is somatically mutated in many cancers including colorectal, ovarian, breast, hepatocellular carcinomas, and glioblastomas. These *PIK3CA* pathogenic variants are located mostly at hot spots within the kinase domain (encoded by exon 20), and result in gain of function implicated in oncogenicity [Samuels et al 2004, Ikenoue et al 2005, Kang et al 2005].

Most (>80%) activating *PIK3CA* pathogenic variants in cancer (Table 10) and PROS (Table 9) cluster at three hot spots: two glutamic acid (Glu) residues at codons 542 and 545, and a histidine (His) residue at codon 1047. The distribution of *PIK3CA* pathogenic variants in cancer was obtained from the Catalogue of Somatic Mutations in Cancer (COSMIC, v85, May 2018). *PIK3CA* pathogenic variants in PROS comprise published cases from larger cohort studies. The risk for tumorigenesis and development of malignancies is a theoretic concern because *PIK3CA* is somatically mutated or overexpressed in many cancers. The pathogenic variants in *PIK3CA* in cancers and in a large proportion of individuals with PROS (especially those with the phenotypes of CLOVES, fibroadipose hyperplasia, and isolated macrodactyly) are most commonly located at hot spots within the helical and kinase domains.

Among the approximately 160 *PIK3CA* pathogenic variants listed in the Catalogue of Somatic Mutations in Cancer (COSMIC), common variants in three amino acids (p.Glu542Lys, p.Glu545Lys in exon 9, and p.His1047Arg and p.His1047Leu in exon 20) account for 80% of tumor-associated *PIK3CA* variants and show the highest oncogenic activity [Samuels et al 2004, Samuels & Ericson 2006, Janku et al 2012]. See Table 10.

Table 10. Common Cancer-Related *PIK3CA* Variants Reported in COSMIC Database

Reference Sequences	DNA Nucleotide Change	Predicted Protein Change	# of Cancer Specimens with Pathogenic Variant
PIK3CA ENST00000643187 NM_006218.4	c.1625G>A	p.Glu542Lys	633
	c.1633G>A	p.Glu545Lys	977
	c.3140A>G	p.His1047Arg	1680
	c.3140A>T	p.His1047Leu	201

COSMIC: Catalogue of Somatic Mutations in Cancer

Chapter Notes

Author Notes

Dr Ghayda Mirzaa is an Associate Professor of Medical Genetics and Pediatrics at the University of Washington School of Medicine. Her research is focused on developmental brain disorders including megalencephaly with multiple publications related to *PIK3CA*-related overgrowth spectrum (PROS) including the natural history, molecular diagnosis, and potential therapies.

Dr John M Graham Jr is a Professor Emeritus of Pediatrics at David Geffen School of Medicine at UCLA and Consulting Clinical Geneticist at Cedars-Sinai Medical Center and Harbor UCLA Medical Center. He has had a long-term clinical interest in PROS with many publications on this topic.

Dr Kim Keppler-Noreuil is a clinical geneticist and Division Chief of Genetics & Metabolism at the University of Wisconsin School of Medicine and Public Health; she has multiple publications related to PROS, including invited review articles and original research focused particularly on the clinical and molecular diagnosis, and potential therapies for PROS.

Acknowledgments

We would like to thank the patients, their families, and our collaborators for their valuable contribution to our knowledge about these disorders.

Author History

Robert Conway, MD; Wayne State University (2013-2021)

William B Dobyns, MD; Seattle Children's Hospital (2013-2021)

John H Graham Jr, MD, ScD (2013-present)

Kim Keppler-Noreuil, MD, FAAP, FACMG (2021-present)

Ghayda Mirzaa, MD, FAAP, FACMG (2013-present)

Revision History

- 6 April 2023 (ma/aa) Revision: expanded information on management of hypoglycemia; Targeted Therapy linked as a Key Section
- 25 August 2022 (aa) Revision: FDA approval of alpelisib for treatment of PROS (Table 6)
- 23 December 2021 (ma) Comprehensive update posted live
- 15 August 2013 (me) Review posted live
- 11 March 2013 (gm) Original submission

References

Literature Cited

- Adams DM, Ricci KW. Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options. *Hematol Oncol Clin North Am.* 2019;33:455-70. PubMed PMID: 31030813.
- Adams DM, Trenor CC, 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Mellow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, Elluru RG, Lucky AW, Weiss B, Azizkhan RG. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. *Pediatrics.* 2016;137:e20153257. PubMed PMID: 26783326.
- Alomari AI. Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. *Clin Dysmorphol.* 2009;18:1-7. PubMed PMID: 19011570.
- Alomari AI. Comments on the diagnosis and management of CLOVES syndrome. *Pediatr Dermatol.* 2011;28:215-6. PubMed PMID: 21504461.
- Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. 2021. A review of mechanisms of disease across PIK3CA-related disorder with vascular malformations. *Orphanet J Rare Dis* 16:306. PubMed PMID: 34238334.
- Clayton-Smith J, Kerr B, Brunner H, Tranebjaerg L, Magee A, Hennekam RC, Mueller RF, Brueton L, Super M, Steen-Johnsen J, Donnai D. Macrocephaly with cutis marmorata, haemangioma and syndactyly--a distinctive overgrowth syndrome. *Clin Dysmorphol.* 1997;6:291-302. PubMed PMID: 9354837.
- Conway RL, Danielpour M, Graham JM Jr. Surgical management of cerebellar tonsillar herniation in three patients with macrocephaly-cutis marmorata telangiectatica congenita. Report of three cases. *J Neurosurg.* 2007a;106:296-301. PubMed PMID: 17465364.
- Conway RL, Pressman BD, Dobyns WB, Danielpour M, Lee J, Sanchez-Lara PA, Butler MG, Zackai E, Campbell L, Saitta SC, Clericuzio CL, Milunsky JM, Hoyme HE, Shieh J, Moeschler JB, Crandall B, Lauzon JL, Viskochil DH, Harding B, Graham JM Jr. Neuroimaging findings in macrocephaly-capillary malformation: a longitudinal study of 17 patients. *Am J Med Genet A.* 2007b;143A:2981-3008. PubMed PMID: 18000912.
- Coste K, Sarret C, Cisse A, Delabaere A, Francannet C, Vanlieferinghen P. Macrocephaly-capillary malformation. A neonatal case *Arch Pediatr.* 2012;19:917-20. PubMed PMID: 22884750.
- Couto JA, Konczyk DJ, Vivero MP, Kozakewich HPW, Upton J, Fu X, Padwa BL, Mulliken JB, Warman ML, Greene AK. Somatic PIK3CA mutations are present in multiple tissues of facial infiltrating lipomatosis. *Pediatr Res.* 2017;82:850-4. PubMed PMID: 28665924.
- Davis S, Ware MA, Zeiger J, Deardorff MA, Grand K, Grimberg A, Hsu S, Kelsey M, Majidi S, Matthew RP, Napier M, Nokoff N, Prasad C, Riggs AC, McKinnon ML, Mirzaa G. Growth hormone deficiency in megalencephaly-capillary malformation syndrome: An association with activating mutations in PIK3CA. *Am J Med Genet A.* 2020;182:162-8. PubMed PMID: 31729162.
- Dekeuleneer V, Seront E, Van Damme A, Boon LM, Vikkula M. Theranostic advances in vascular malformations. *J Invest Dermatol.* 2020;140:756-63. PubMed PMID: 32200879.
- D'Gama AM, Geng Y, Couto JA, Martin B, Boyle EA, LaCoursiere CM, Hossain A, Hatem NE, Barry BJ, Kwiatkowski DJ, Vinters HV, Barkovich AJ, Shendure J, Mathern GW, Walsh CA, Poduri A. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. *Ann Neurol.* 2015;77:720-5. PubMed PMID: 25599672.

- Di Rocco C, Battaglia D, Pietrini D, Piastra M, Massimi L. Hemimegalencephaly: clinical implications and surgical treatment. *Childs Nerv Syst.* 2006;22:852-66. PubMed PMID: 16821075.
- Douzgou S, Rawson M, Baselga E, Danielpour M, Faivre L, Kashanian A, Keppler-Noreuil KM, Kuentz P, Mancini GMS, Maniere MC, Martinez-Glez V, Parker VE, Semple RK, Srivastava S, Vabres P, De Wit MY, Graham JM Jr, Clayton-Smith J, Mirzaa GM, Biesecker LG. A standard of care for individuals with PIK3CA-related disorders: an international expert consensus statement. *Clin Genet.* 2022;101:32-47. PubMed PMID: 34240408.
- Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat Rev Genet.* 2006;7:606-19. PubMed PMID: 16847462.
- Erickson J, McAuliffe W, Blennerhassett L, Halbert A. Fibroadipose vascular anomaly treated with sirolimus: successful outcome in two patients. *Pediatr Dermatol.* 2017;34:e317-e320 PubMed PMID: 29144050.
- Gripp KW, Baker L, Kandula V, Conard K, Scavina M, Napoli JA, Griffin GC, Thacker M, Knox RG, Clark GR, Parker VE, Semple R, Mirzaa G, Keppler-Noreuil KM. Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation. *Am J Med Genet A.* 2016;170:2559-69. PubMed PMID: 27191687.
- Gripp KW, Hopkins E, Vinkler C, Lev D, Malinger G, Lerman-Sagie T, Dobyns WB. Significant overlap and possible identity of macrocephaly capillary malformation and megalencephaly polymicrogyria-polydactyly hydrocephalus syndromes. *Am J Med Genet A.* 2009;149A:868-76. PubMed PMID: 19353582.
- Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, Hoyoux C, Chopinet C, Clapuyt P, Hammer F, Vikkula M, Boon LM. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study. *Orphanet J Rare Dis.* 2018;13:191. PubMed PMID: 30373605.
- Huchtagowder V, Shenoy A, Corliss M, Vigh-Conrad KA, Storer C, Grange DK, Cottrell CE. Utility of clinical high-depth next generation sequencing for somatic variant detection in the PIK3CA-related overgrowth spectrum. *Clin Genet.* 2017;91:79-85. PubMed PMID: 27307077.
- Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, Asaoka Y, Matsumura M, Kawabe T, Omata M. 2005. Functional analysis of PIK3CA gene mutations in human colorectal cancer. *Cancer Res* 65:4562-7. PubMed PMID: 15930273.
- Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. *Oncotarget.* 2012;3:1566-75. PubMed PMID: 23248156.
- Jansen LA, Mirzaa GM, Ishak GE, O'Roak BJ, Hiatt JB, Roden WH, Gunter SA, Christian SL, Collins S, Adams C, Rivière JB, St-Onge J, Ojemann JG, Shendure J, Hevner RF, Dobyns WB. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. *Brain.* 2015;138:1613-28. PubMed PMID: 25722288.
- Kang S, Bader AG, Vogt PK. 2005. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. *Proc Natl Acad Sci USA* 102:802-7. PubMed PMID: 15647370.
- Keppler-Noreuil KM, Lozier J, Oden N, Taneja A, Burton-Akright J, Sapp JC, Biesecker LG. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome. *Am J Med Genet C Semin Med Genet.* 2019;181:571-81. PubMed PMID: 31490637.
- Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. *Am J Med Genet A.* 2015;167A:287-95. PubMed PMID: 25557259.
- Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, Tosi LL, Huson SM, Whitehouse RW, Jakkula E, Grant I, Balasubramanian M, Chandler KE, Fraser JL, Gucev Z, Crow YJ, Brennan LM, Clark R, Sellars EA, Pena LD, Krishnamurty V, Shuen A, Braverman N, Cunningham ML,

- Sutton VR, Tasic V, Graham JM Jr, Geer J Jr, Henderson A, Semple RK, Biesecker LG. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. *Am J Med Genet A*. 2014;164A:1713-33. PubMed PMID: 24782230.
- Kuentz P, St-Onge J, Duffourd Y, Courcet JB, Carmignac V, Jouan T, Sorlin A, Abasq-Thomas C, Albuissou J, Amiel J, Amram D, Arpin S, Attie-Bitach T, Bahi-Buisson N, Barbarot S, Baujat G, Bessis D, Boccarda O, Bonnière M, Boute O, Bursztejn AC, Chiaverini C, Cormier-Daire V, Coubes C, Delobel B, Edery P, Chehadeh SE, Francannet C, Geneviève D, Goldenberg A, Haye D, Isidor B, Jacquemont ML, Khau Van Kien P, Lacombe D, Martin L, Martinovic J, Maruani A, Mathieu-Dramard M, Mazereeuw-Hautier J, Michot C, Mignot C, Miquel J, Morice-Picard F, Petit F, Phan A, Rossi M, Touraine R, Verloes A, Vincent M, Vincent-Delorme C, Whalen S, Willems M, Marle N, Lehalle D, Thevenon J, Thauvin-Robinet C, Hadj-Rabia S, Favier L, Vabres P, Rivière JB. Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. *Genet Med*. 2017;19:989-97. PubMed PMID: 28151489.
- Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP, Warman ML. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. *Am J Hum Genet*. 2012;90:1108-15. PubMed PMID: 22658544.
- Kwan SY, Shyu HY, Lin JH, Wong TT, Chang KP, Yiu CH. Corpus callosotomy in a patient of hemimegalencephaly and Lennox-Gastaut syndrome. *Brain Dev*. 2008;30:643-6. PubMed PMID: 18439776.
- Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. *Nat Genet*. 2012;44:941-5. PubMed PMID: 22729223.
- Leiter SM, Parker VER, Welters A, Knox R, Rocha N, Clark G, Payne F, Lotta L, Harris J, Guerrero-Fernández J, González-Casado I, García-Miñaur S, Gordo G, Wareham N, Martínez-Glez V, Allison M, O'Rahilly S, Barroso I, Meissner T, Davies S, Hussain K, Temple K, Barreda-Bonis AC, Kummer S, Semple RK. Hypoinsulinaemic, hypoketotic hypoglycaemia due to mosaic genetic activation of PI3-kinase. *Eur J Endocrinol*. 2017;177:175-86. PubMed PMID: 28566443.
- Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotziou C, Dixon AK, Helliwell T, O'Rahilly S, Savage DB, Wakelam MJ, Barroso I, Biesecker LG, Semple RK. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. *Nat Genet*. 2012;44:928-33. PubMed PMID: 22729222.
- Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovée JV, Rialon KL, Guevara CJ, Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, Maclellan RA, Mulliken JB, Rahbar R, Spencer SA, Trenor CC 3rd, Upton J, Zurakowski D, Perkins JA, Kirsh A, Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA, Murillo R. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. *J Pediatr*. 2015;166:1048-54.e1. PubMed PMID: 25681199.
- Maines E, Franceschi R, Martinelli D, Soli F, Lepri FR, Piccoli G, Soffiati M. Hypoglycemia due to PI3K/AKT/mTOR signaling pathway defects: two novel cases and review of the literature. *Hormones (Athens)*. 2021;20:623-40. PubMed PMID: 33876391.
- Martínez-Glez V, Romanelli V, Mori MA, Gracia R, Segovia M, González-Meneses A, López-Gutierrez JC, Gean E, Martorell L, Lapunzina P. Macrocephaly-capillary malformation: Analysis of 13 patients and review of the diagnostic criteria. *Am J Med Genet A*. 2010;152A:3101-6. PubMed PMID: 21077203.
- Martínez-Lage JF, Guillén-Navarro E, Almagro MJ, Felipe-Murcia M, López López-Guerrero A, Galarza M. Hydrocephalus and Chiari type 1 malformation in macrocephaly-cutis marmorata telangiectatica congenita: a case-based update. *Childs Nerv Syst*. 2010;26:13-8. PubMed PMID: 19763591.

- McBride KL, Varga EA, Pastore MT, Prior TW, Manickam K, Atkin JF, Herman GE. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. *Autism Res.* 2010;3:137-41. PubMed PMID: 20533527.
- Mills JR, Moyer AM, Kipp BR, Poplawski AB, Messiaen LM, Babovic-Vuksanovic D. Unilateral vestibular schwannoma and meningiomas in a patient with PIK3CA-related segmental overgrowth: Co-occurrence of mosaicism for 2 rare disorders. *Clin Genet.* 2018;93:187-90. PubMed PMID: 28737257.
- Mirzaa GM, Conway RL, Gripp KW, Lerman-Sagie T, Siegel DH, deVries LS, Lev D, Kramer N, Hopkins E, Graham JM Jr, Dobyns WB. Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. *Am J Med Genet A.* 2012;158A:269-91. PubMed PMID: 22228622.
- Mirzaa G, Timms AE, Conti V, Boyle EA, Girisha KM, Martin B, Kircher M, Olds C, Juusola J, Collins S, Park K, Carter M, Glass I, Krägeloh-Mann I, Chitayat D, Parikh AS, Bradshaw R, Torti E, Braddock S, Burke L, Ghedia S, Stephan M, Stewart F, Prasad C, Napier M, Saitta S, Straussberg R, Gabbett M, O'Connor BC, Keegan CE, Yin LJ, Lai AHM, Martin N, McKinnon M, Addor MC, Boccuto L, Schwartz CE, Lanoel A, Conway RL, Devriendt K, Tatton-Brown K, Pierpont ME, Painter M, Worgan L, Reggin J, Hennekam R, Tsuchiya K, Pritchard CC, Aracena M, Gripp KW, Cordisco M, Van Esch H, Garavelli L, Curry C, Goriely A, Kayserilli H, Shendure J, Graham J Jr, Guerrini R, Dobyns WB. PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. *JCI Insight.* 2016;1:e87623. PubMed PMID: 27631024.
- Moore CA, Toriello HV, Abuelo DN, Bull MJ, Curry CJ, Hall BD, Higgins JV, Stevens CA, Twersky S, Weksberg R, Dobyns WB. Macrocephaly-cutis marmorata telangiectatica congenita: a distinct disorder with developmental delay and connective tissue abnormalities. *Am J Med Genet.* 1997;70:67-73. PubMed PMID: 9129744.
- Nyberg RH, Uotila J, Kirkinen P, Rosendahl H. Macrocephaly-cutis marmorata telangiectatica congenita syndrome--prenatal signs in ultrasonography. *Prenat Diagn.* 2005;25:129-32. PubMed PMID: 15712320.
- Padilla CA, Bárcena JA, López-Grueso MJ, Requejo-Aguilar R. The regulation of TORC1 pathway by the yeast chaperones Hsp31 is mediated by SFP1 and affects proteasomal activity. *Biochim Biophys Acta Gen Subj.* 2019;1863:534-46. PubMed PMID: 30578832.
- Parker VE, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, Sapp JC, Andrews K, Bardou M, Chen KY, Darling TN, Gautier E, Goldspiel BR, Hadj-Rabia S, Harris J, Kounidas G, Kumar P, Lindhurst MJ, Loffroy R, Martin L, Phan A, Rother KI, Widemann BC, Wolters PL, Coubes C, Pinson L, Willems M, Vincent-Delorme C, Vabres P, Semple RK, Biesecker LG, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. *Genet Med.* 2019;21:1189-98. PubMed PMID: 30270358.
- Peterman CM, Fevurly RD, Alomari AI, Trenor CC 3rd, Adams DM, Vadeboncoeur S, Liang MG, Greene AK, Mulliken JB, Fishman SJ. Sonographic screening for Wilms tumor in children with CLOVES syndrome. *Pediatr Blood Cancer.* 2017;64. PubMed PMID: 27555087.
- Pirozzi F, Berkseth M, Shear R, Gonzalez L, Timms AE, Sulc J, Pao E, Oyama N, Forzano F, Conti V, Guerrini R, Doherty ES, Saitta SC, Lockwood CM, Pritchard CC, Dobyns WB, Novotny E, Wright J, Saneto RP, Friedman S, Hauptman J, Ojemann J, Kapur RP, Mirzaa GMM. Profiling PI3K-AKT-MTOR variants in focal brain malformations reveals new insights for diagnostic care. *Brain.* In press. PubMed PMID: 35355055.
- Postema FAM, Hopman SMJ, Aalfs CM, Berger LPV, Bleeker FE, Dommering CJ, Jongmans MCJ, Letteboer TGW, Olderode-Berends MJW, Wagner A, Hennekam RC, Merks JHM. Childhood tumours with a high probability of being part of a tumour predisposition syndrome; reason for referral for genetic consultation. *Eur J Cancer.* 2017;80:48-54. PubMed PMID: 28544908.

- Ricci KW, Hammill AM, Mobberley-Schuman P, Nelson SC, Blatt J, Bender JLG, McCuaig CC, Synakiewicz A, Frieden IJ, Adams DM. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. *Pediatr Blood Cancer*. 2019;66:e27614. PubMed PMID: 30672136.
- Rivière JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggari AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL; Finding of Rare Disease Genes (FORGE) Canada Consortium, Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. *Nat Genet*. 2012;44:934-40. PubMed PMID: 22729224.
- Robertson SP, Gattas M, Rogers M, Adès LC. Macrocephaly--cutis marmorata telangiectatica congenita: report of five patients and a review of the literature. *Clin Dysmorphol*. 2000;9:1-9. PubMed PMID: 10649789.
- Rodriguez-Laguna L, Agra N, Ibañez K, Oliva-Molina G, Gordo G, Khurana N, Hominick D, Beato M, Colmenero I, Herranz G, Torres Canizalez JM, Rodríguez Pena R, Vallespín E, Martín-Arenas R, Del Pozo Á, Villaverde C, Bustamante A, Ayuso C, Lapunzina P, Lopez-Gutierrez JC, Dellinger MT, Martinez-Glez V. Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly. *J Exp Med*. 2019;216:407-18. PubMed PMID: 30591517.
- Sadick M, Müller-Wille R, Wildgruber M, Wohlgemuth WA. Vascular anomalies (part i): classification and diagnostics of vascular anomalies. *Rofo*. 2018;190:825-35. PubMed PMID: 29874693.
- Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. *Curr Opin Oncol*. 2006;18:77-82. PubMed PMID: 16357568.
- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. *Science*. 2004;304:554. PubMed PMID: 15016963.
- Sapp JC, Turner JT, van de Kamp JM, van Dijk FS, Lowry RB, Biesecker LG. Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients. *Am J Med Genet A*. 2007;143A:2944-58. PubMed PMID: 17963221.
- Schwartz IVD, Felix TM, Riegel M, Schüler-Faccini L. Atypical macrocephaly-cutis marmorata telangiectatica congenita with retinoblastoma. *Clin Dysmorphol*. 2002;11:199-202. PubMed PMID: 12072801.
- Seront E, Van Damme A, Boon LM, Vikkula M. Rapamycin and treatment of venous malformations. *Curr Opin Hematol*. 2019;26:185-92. PubMed PMID: 30855337.
- Van Damme A, Seront E, Dekeuleener V, Boon LM, Vikkula M. New and emerging targeted therapies for vascular malformations. *Am J Clin Dermatol*. 2020;21:657-68. PubMed PMID: 32557381.
- Vogels A, Devriendt K, Legius E, Decock P, Marien J, Hendrickx G, Fryns JP. The macrocephaly-cutis marmorata telangiectatica congenita syndrome. Long-term follow-up data in 4 children and adolescents. *Genet Couns*. 1998;9:245-53. PubMed PMID: 9894160.
- Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, Burrows P, Frieden IJ, Garzon MC, Lopez-Gutierrez JC, Lord DJ, Mitchel S, Powell J, Prendiville J, Vikkula M, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. *Pediatrics*. 2015;136:e203-14. PubMed PMID: 26055853.
- Zampino G, Leoni C, Buonuono PS, Rana I, Onesimo R, Macchiaiolo M, et al. An open-label, Phase I/II study of miransertib (ARQ 092), an oral pan-AKT inhibitor, in patients (pts) with PIK3CA-related overgrowth spectrum (PROS) and Proteus syndrome (PS): study design and preliminary results ([NCT03094832](#)). Gothenburg, Sweden: European Society of Human Genetics Conference; June 15-18, 2019; Abstract C 18.6.

Zenner K, Cheng CV, Jensen DM, Timms AE, Shivaram G, Bly R, Ganti S, Whitlock KB, Dobyns WB, Perkins J, Bennett JT. Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations. *JCI Insight*. 2019;4:e129884. PubMed PMID: 31536475.

License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: admasst@uw.edu.